Alzheimer’s disease: An overview of the current treatments

Carolina Serrano-Larrea, David Clavijo-Calderón
{"title":"Alzheimer’s disease: An overview of the current treatments","authors":"Carolina Serrano-Larrea, David Clavijo-Calderón","doi":"10.21931/RB/CS/2019.02.01.17","DOIUrl":null,"url":null,"abstract":"Alzheimer’s disease (AD) affects millions of people around the world and although there are treatments that help control symptoms and slow down the progress of the disease, there is still no cure. Current treatments include three acetylcholine inhibitors, a glutamate inhibitor and a combination of the two. Due to the failure of hundreds of clinical trials with monotherapies, multitarget treatments are currently being investigated that consider both brain and peripheral factors. Gene therapy is one of the most promising therapies to treat and prevent the development of AD. Nowadays, there is no available medical treatment based on gene therapy to treat AD; however, there are treatments in phase 1 and phase 2 clinical trials with promising results. In this review, we will focus on the most important gene therapy treatments, CERE-110 (adeno-associated virus AAV2-Nerve Growth Factor), Intracerebral AAV gene delivery of APOE2 and gene therapy using PPARγ-coactivator-1α(PGC-1α)","PeriodicalId":214615,"journal":{"name":"Humboldt kolleg Ibarra 2019","volume":"197 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Humboldt kolleg Ibarra 2019","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21931/RB/CS/2019.02.01.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Alzheimer’s disease (AD) affects millions of people around the world and although there are treatments that help control symptoms and slow down the progress of the disease, there is still no cure. Current treatments include three acetylcholine inhibitors, a glutamate inhibitor and a combination of the two. Due to the failure of hundreds of clinical trials with monotherapies, multitarget treatments are currently being investigated that consider both brain and peripheral factors. Gene therapy is one of the most promising therapies to treat and prevent the development of AD. Nowadays, there is no available medical treatment based on gene therapy to treat AD; however, there are treatments in phase 1 and phase 2 clinical trials with promising results. In this review, we will focus on the most important gene therapy treatments, CERE-110 (adeno-associated virus AAV2-Nerve Growth Factor), Intracerebral AAV gene delivery of APOE2 and gene therapy using PPARγ-coactivator-1α(PGC-1α)
阿尔茨海默病:当前治疗的概述
阿尔茨海默病(AD)影响着全世界数百万人,尽管有治疗方法可以帮助控制症状并减缓疾病的进展,但仍然没有治愈方法。目前的治疗方法包括三种乙酰胆碱抑制剂,一种谷氨酸抑制剂和两者的结合。由于数百个单一疗法的临床试验失败,目前正在研究同时考虑大脑和周围因素的多靶点治疗。基因疗法是治疗和预防阿尔茨海默病最有前途的疗法之一。目前,还没有基于基因疗法的医学治疗方法来治疗AD;然而,在1期和2期临床试验中也有一些治疗方法取得了令人鼓舞的结果。在这篇综述中,我们将重点关注最重要的基因治疗方法,CERE-110(腺相关病毒aav2 -神经生长因子),脑内AAV基因递送APOE2和ppar γ-共激活因子-1α(PGC-1α)的基因治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信